Revelation Biosciences, Inc. - Common Stock (REVB)

Revelation Biosciences (REVB) reports Q2 2025 earnings with a wider-than-expected loss of $(7.01) per share. Cash runway extends to December 2025, while Phase 1b Gemini trial data for CKD is expected soon. Stock dips 5.1% pre-market.

U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices were trading slightly higher.

The company is nearing completion of enrollment in its Phase 1b Gemini trial for CKD, with topline results expected shortly.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Unusual volume stocks are being observed in Tuesday's session.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.